The inhibition of CIP2A has been shown to determine the effect of bortezomib on apoptosis and PP2A-dependent AKT inactivation in hepatocellular carcinoma indicating that CIP2A may be a biomarker for predicting clinical response of bortezomib in hepatocellular carcinoma treatment [91]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.